Eflornithine topical - Bristol-Myers Squibb/Gillette

Drug Profile

Eflornithine topical - Bristol-Myers Squibb/Gillette

Alternative Names: BMS-203522; Eflornithine cream; Eflornithine HCl; Eflornithine hydrochloride topical; Vaniqa

Latest Information Update: 14 May 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb; Gillette
  • Developer Bristol-Myers Squibb; Clinuvel Pharmaceuticals; Stiefel Laboratories
  • Class Basic amino acids; Diamino amino acids; Small molecules
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hirsutism

Most Recent Events

  • 07 May 2015 Eflornithine topical licensed to Cipher Pharmaceuticals in Canada
  • 19 Dec 2012 SkinMedica has been acquired by Allergan
  • 22 Jul 2009 Stiefel Laboratories has been acquired by GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top